Corcept Reports Positive Phase 2 Data for Lifyorli Combination
Corcept reported positive Phase 2 data for a Lifyorli combination in platinum-resistant ovarian cancer.
Corcept reported positive Phase 2 data for a Lifyorli combination in platinum-resistant ovarian cancer.